Satheesh C. Thungappa
Bengaluru, KA 560027, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience.
Journal: Scientific reports
Published: September 11, 2024
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Journal: Lancet (London, England)
Published: August 06, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Journal: Journal of hepatology
Published: February 16, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 22, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Journal: Future oncology (London, England)
Published: September 06, 2023
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 12, 2022
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Journal: NEJM evidence
Published: August 01, 2022
Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies.
Journal: Journal of cancer research and therapeutics
Published: March 16, 2021
Landscape of clinically actionable mutations in breast cancer 'A cohort study'.
Journal: Translational oncology
Published: July 25, 2020
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found….
Journal: ESMO open
Published: January 16, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026